Kathera Bioscience is developing broad-spectrum antifungal therapies that target novel fungal enzymes, addressing the limitations of existing treatments such as toxicity and drug resistance. The company's approach aims to provide effective monotherapy or combination therapy options for life-threatening fungal infections affecting millions globally.
Funding
$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of people worldwide suffer from life-threatening fungal infections, but the limited classes of available antifungal drugs have drawbacks, including toxicity, drug-drug interactions, inconvenient dosing, and increasing incidence of resistance. The rise of drug-resistant fungi has prompted the CDC to classify certain Candida and Aspergillus species as "Serious" and "Urgent Threats."
Solution
Kathera Bioscience is developing broad-spectrum antifungal therapies that target novel fungal enzymes, overcoming the limitations of existing treatments. Their approach aims to provide effective monotherapy or combination therapy options for life-threatening fungal infections. By targeting previously unexploited fungal enzymes, KatheraBio's drugs can potentially circumvent existing resistance mechanisms and offer a new line of defense against these infections. The company's technology is designed to address the urgent need for next-generation antifungal drugs.
Target Audience
The primary target audience includes individuals at risk of life-threatening fungal infections, as well as healthcare providers seeking more effective and less toxic treatment options.
Features
- Targets novel fungal enzymes with no existing FDA-approved drugs.
- Designed for use as monotherapy or in combination with existing antifungals.
- Aims to overcome limitations of current antifungals, such as toxicity and drug resistance.
- Broad-spectrum activity against a range of fungal pathogens.